Literature DB >> 36261234

Characterising methamphetamine use to inform health and social policies in Manitoba, Canada: a protocol for a retrospective cohort study using linked administrative data.

Nathan C Nickel1,2, Jennifer E Enns3, Amy Freier3, Scott C McCulloch3, Mariette Chartier3, Hera J M Casidsid3, Oludolapo Deborah Balogun3, Drew Mulhall4, Roxana Dragan3, Joykrishna Sarkar3, James Bolton5, Geoffrey Konrad5, Wanda Phillips-Beck6, Julianne Sanguins7, Carolyn Shimmin8, Neil McDonald9, Javier Mignone10, Aynslie Hinds10.   

Abstract

INTRODUCTION: Rising use of methamphetamine is causing significant public health concern in Canada. The biological and behavioural effects of methamphetamine range from wakefulness, vigour and euphoria to adverse physical health outcomes like myocardial infarction, haemorrhagic stroke, arrhythmia and seizure. It can also cause severe psychological complications such as psychosis. National survey data point to increasing rates of methamphetamine use, as well as increasing ease of access and serious methamphetamine-related harms. There is an urgent need for evidence to address knowledge gaps, provide direction to harm reduction and treatment efforts and inform health and social policies for people using methamphetamine. This protocol describes a study that aims to address this need for evidence.
METHODS: The study will use linked, whole population, de-identified administrative data from the Manitoba Population Research Data Repository. The cohort will include individuals in the city of Winnipeg, Manitoba, who came into contact with the health system for reasons related to methamphetamine use from 2013 to 2021 and a comparison group matched on age, sex and geography. We will describe the cohort's sociodemographic characteristics, calculate incidence and prevalence of mental disorders associated with methamphetamine use and examine rates of health and social service use. We will evaluate the use of olanzapine pharmacotherapy in reducing adverse emergency department outcomes. In partnership with Indigenous co-investigators, outcomes will be stratified by First Nations and Métis identity. ETHICS AND DISSEMINATION: The study was approved by the University of Manitoba Health Research Ethics Board, and access datasets have been granted by all data providers. We also received approval from the First Nations Health and Social Secretariat of Manitoba's Health Information Research Governance Committee and the Manitoba Métis Federation. Dissemination will be guided by an 'Evidence 2 Action' group of public rightsholders, service providers and knowledge users who will ensure that the analyses address the critical issues. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; mental health; substance misuse

Mesh:

Substances:

Year:  2022        PMID: 36261234      PMCID: PMC9582321          DOI: 10.1136/bmjopen-2022-062127

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   3.006


  48 in total

Review 1.  The burden and management of crystal meth use.

Authors:  Jane A Buxton; Naomi A Dove
Journal:  CMAJ       Date:  2008-06-03       Impact factor: 8.262

2.  Pharmacotherapy management of schizophrenia for family physicians.

Authors:  Japheth Bool; Alex Crawley; Annabelle Wanson; Breanna Davis; Katelyn Halpape
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

Review 3.  Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings.

Authors:  Roland Härtel-Petri; Anne Krampe-Scheidler; Wolf-Dietrich Braunwarth; Ursula Havemann-Reinecke; Peter Jeschke; Winfried Looser; Stephan Mühlig; Ingo Schäfer; Norbert Scherbaum; Lydia Bothe; Corinna Schaefer; Willem Hamdorf
Journal:  Pharmacopsychiatry       Date:  2017-04-26       Impact factor: 5.788

4.  Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada.

Authors:  Farihah Ali; Cayley Russell; Frishta Nafeh; Jürgen Rehm; Sean LeBlanc; Tara Elton-Marshall
Journal:  Int J Drug Policy       Date:  2021-04-10

5.  Performance Measures of Diagnostic Codes for Detecting Opioid Overdose in the Emergency Department.

Authors:  Christopher Rowe; Eric Vittinghoff; Glenn-Milo Santos; Emily Behar; Caitlin Turner; Phillip O Coffin
Journal:  Acad Emerg Med       Date:  2017-03-17       Impact factor: 3.451

Review 6.  Methamphetamine psychosis: epidemiology and management.

Authors:  Suzette Glasner-Edwards; Larissa J Mooney
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

7.  Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure.

Authors:  Ruth Salo; Catherine Fassbender; Ana-Maria Iosif; Stefan Ursu; Martin H Leamon; Cameron Carter
Journal:  Psychiatry Res       Date:  2013-07-26       Impact factor: 3.222

8.  Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use.

Authors:  Hyungjin Myra Kim; Eric G Smith; Claire M Stano; Dara Ganoczy; Kara Zivin; Heather Walters; Marcia Valenstein
Journal:  BMC Health Serv Res       Date:  2012-01-23       Impact factor: 2.655

Review 9.  Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts.

Authors:  Seyed Ramin Radfar; Richard A Rawson
Journal:  Addict Health       Date:  2014 Summer-Autumn

10.  Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis.

Authors:  Dan Lewer; Joseph Freer; Emma King; Sarah Larney; Louisa Degenhardt; Emily J Tweed; Vivian D Hope; Magdalena Harris; Tim Millar; Andrew Hayward; Dan Ciccarone; Katherine I Morley
Journal:  Addiction       Date:  2020-02-10       Impact factor: 7.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.